Affiliations 1 Department of Pathology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. 2 Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. 3 Department of Pathology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China. 4 Department of Pathology, Xuzhou Medical University, Xuzhou, China. 5 Blood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Background: CD5-positive diffuse large B-cell lymphoma showed poor prognosis in the rituximab era, with limited research on its genetic characteristics and cell of origin . We aimed to demonstrate the molecular characteristics of CD5+ DLBCL and to discover potential prognostic factors. Methods: We included 24 cases of CD5+ DLBCL and 23 CD5-negative counterparts and collected their clinicopathological features. Targeted DNA sequencing of 475 lymphoma-related genes was performed, and all cases w...更多
Background: CD5-positive diffuse large B-cell lymphoma showed poor prognosis in the rituximab era, with limited research on its genetic characteristics and cell of origin . We aimed to demonstrate the molecular characteristics of CD5+ DLBCL and to discover potential prognostic factors. Methods: We included 24 cases of CD5+ DLBCL and 23 CD5-negative counterparts and collected their clinicopathological features. Targeted DNA sequencing of 475 lymphoma-related genes was performed, and all cases were assigned to distinct genetic subtypes using the LymphGen tool. The COO was determined by the Lymph2Cx assay. The Kaplan-Meier method and Cox proportional hazards model were applied to identify the possible prognostic factors. Results: Compared with their CD5- counterparts, patients with CD5+ DLBCL tended to have a worse prognosis and a higher incidence of MYD88L265P and CD79B double mutation subtype and activated B cell-like subtype , as determined by next-generation sequencing and Lymph2Cx, respectively. Moreover, PIM1, MYD88, and KMT2D mutations were detected more frequently in CD5+ DLBCL cases . According to multivariate analysis, MYC/BCL2 double expression and ABC subtype were correlated with unfavorable overall survival . High mRNA expression of SERPINA9 and MME showed a significant correlation with a better OS, and high expression of MME showed a significant correlation with better progression-free survival in CD5+ DLBCL. Conclusion: The genetic profile of CD5+ DLBCL is characterized by PIM1, MYD88, and KMT2D mutations, with a higher incidence of MCD and ABC subtypes. MYC/BCL2 double expression, ABC subtype, and mRNA expression of SERPINA9 and MME are independently predictive of the prognosis of CD5+ DLBCL.收起
